Every material Form 8-K BeOne Medicines Ltd. has filed with the SEC since August 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
BeOne Medicines reported third quarter 2026 total revenue of $1.9 billion, up 34% from the prior year, and GAAP diluted EPS per ADS of $3.28 versus $1.09. The company raised its full-year 2026 total revenue guidance to $6.9 billion to $7.0 billion from $6.6 billion to $6.8 billion, and raised GAAP operating income guidance to $1.2 billion to $1.3 billion.
Q3 2026 total revenue $1.9 billion, up 34%; BRUKINSA global revenue $1.4 billion, up 34%
GAAP diluted EPS per ADS $3.28 vs $1.09; non-GAAP diluted EPS per ADS $4.59 vs $2.65
FY 2026 total revenue guidance raised to $6.9 billion to $7.0 billion from $6.6 billion to $6.8 billion
Q3 GAAP gross margin 88% vs 86%, which includes a $22 million non-cash impairment tied to discontinuing POBEVCY promotion
BeOne Medicines filed its 2026 interim report for the six months ended June 30, 2026, with Shanghai's STAR Market and furnished an R&D expense breakdown under Item 2.02. The filing gives total R&D expenses of $1.15 billion for the period versus $1.01 billion a year earlier, but it does not report revenue, net income or EPS, and the full report is in Chinese only.
Total R&D expenses were $1.15 billion for the six months ended June 30, 2026, versus $1.01 billion for the same period in 2025.
Internal R&D expenses were $718.4 million, up from $606.5 million; external R&D expenses were $435.1 million, up from $400.3 million.
BRUKINSA R&D expenses fell to $42.7 million from $63.0 million, and BEQALZI R&D expenses fell to $74.0 million from $94.0 million.
The STAR Interim Report is available only in Chinese on the Shanghai Stock Exchange website and is not filed with the SEC.
BeOne Medicines reported second-quarter 2026 total revenue of $1.7 billion, up 30% from the prior year, and GAAP net income of $237 million, compared with $94 million a year earlier. The company raised its full-year 2026 total revenue guidance to $6.6 billion to $6.8 billion from $6.3 billion to $6.5 billion, which points to higher expected sales for shareholders.
Q2 2026 total revenue $1.7 billion, up 30%; BRUKINSA global revenue $1.2 billion, up 31%
GAAP diluted EPS per ADS $2.05 for Q2 2026, versus $0.84 in Q2 2025
2026 total revenue guidance raised to $6.6 billion to $6.8 billion; GAAP operating income guidance raised to $1.0 billion to $1.1 billion
Q2 2026 free cash flow of $435 million, up 98% from $220 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every BeOne Medicines Ltd. filing is on SEC EDGAR ↗. 8-K briefs of other companies →